We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cronos Group (CRON) Stock Moves -0.36%: What You Should Know
Read MoreHide Full Article
Cronos Group (CRON - Free Report) closed at $11.13 in the latest trading session, marking a -0.36% move from the prior day. This move was narrower than the S&P 500's daily loss of 1.58%. Meanwhile, the Dow lost 1.99%, and the Nasdaq, a tech-heavy index, lost 1.63%.
Coming into today, shares of the cannabis company had gained 30.95% in the past month. In that same time, the Finance sector lost 8.61%, while the S&P 500 lost 6.62%.
Wall Street will be looking for positivity from CRON as it approaches its next earnings report date. This is expected to be April 29, 2019. On that day, CRON is projected to report earnings of -$0.01 per share, which would represent a year-over-year decline of 200%. Our most recent consensus estimate is calling for quarterly revenue of $7.46 million, up 487.4% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.05 per share and revenue of $14.29 million, which would represent changes of -600% and +348.65%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for CRON. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 25% lower within the past month. CRON currently has a Zacks Rank of #4 (Sell).
The Financial - Investment Management industry is part of the Finance sector. This group has a Zacks Industry Rank of 158, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cronos Group (CRON) Stock Moves -0.36%: What You Should Know
Cronos Group (CRON - Free Report) closed at $11.13 in the latest trading session, marking a -0.36% move from the prior day. This move was narrower than the S&P 500's daily loss of 1.58%. Meanwhile, the Dow lost 1.99%, and the Nasdaq, a tech-heavy index, lost 1.63%.
Coming into today, shares of the cannabis company had gained 30.95% in the past month. In that same time, the Finance sector lost 8.61%, while the S&P 500 lost 6.62%.
Wall Street will be looking for positivity from CRON as it approaches its next earnings report date. This is expected to be April 29, 2019. On that day, CRON is projected to report earnings of -$0.01 per share, which would represent a year-over-year decline of 200%. Our most recent consensus estimate is calling for quarterly revenue of $7.46 million, up 487.4% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.05 per share and revenue of $14.29 million, which would represent changes of -600% and +348.65%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for CRON. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 25% lower within the past month. CRON currently has a Zacks Rank of #4 (Sell).
The Financial - Investment Management industry is part of the Finance sector. This group has a Zacks Industry Rank of 158, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.